Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cytosorbents Corporation - Common Stock (NQ:CTSO)

4.231 +0.331 (+8.48%)
Delayed Quote Updated: 12:55 PM EDT, Oct 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cytosorbents Corporation - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
The Analyst Verdict: CytoSorbents In The Eyes Of 4 Experts ↗
 
Via Benzinga
News headline image
Earnings Scheduled For March 31, 2025 ↗
 
Via Benzinga
News headline image
Insights into CytoSorbents's Upcoming Earnings ↗
 
Via Benzinga
News headline image
Expert Outlook: CytoSorbents Through The Eyes Of 7 Analysts ↗
 
Via Benzinga
News headline image
Analyst Scoreboard: 5 Ratings For CytoSorbents ↗
 
Via Benzinga
News headline image
CytoSorbents Postpones Earnings Release to Allow More Time to Complete Annual Audit Following the Passing of Corporate Controller
The Company reaffirms previously provided preliminary financial results for the quarter and full year ended December 31, 2024, and continues to expect regulatory decisions on DrugSorb™-ATR marketing... 
From CytoSorbents
Via GlobeNewswire
News headline image
CytoSorbents to Report Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
From CytoSorbents
Via GlobeNewswire
News headline image
CytoSorbents Further Strengthens Balance Sheet with Exercise of Previously Announced Series A Right Warrants
1,417,208 Series A Right Warrants Exercised at $1.13 Per Share, Providing $1.6 Million in Aggregate Gross Proceeds 
From CytoSorbents
Via GlobeNewswire
News headline image
CytoSorbents Strengthens Balance Sheet with Closing of Oversubscribed Rights Offering
From CytoSorbents
Via GlobeNewswire
News headline image
CytoSorbents Expands Global Footprint with Opening of New Regional Sales Subsidiary in Dubai
From CytoSorbents
Via GlobeNewswire
News headline image
Health Care Equipment Supplier CytoSorbents Shares Dip Despite Projected Revenue Growth ↗
CytoSorbents is progressing with U.S. FDA and Health Canada reviews for its DrugSorb-ATR device. 
Via Benzinga
Topics Supply Chain
News headline image
CytoSorbents Reports Preliminary Unaudited Fourth Quarter and Full-Year 2024 Product Revenue
From CytoSorbents
Via GlobeNewswire
News headline image
Expert Outlook: CytoSorbents Through The Eyes Of 5 Analysts ↗
 
Via Benzinga
News headline image
CytoSorbents Rights Offering Begins
To Participate, Eligible Stockholders Should Consult Their Broker or Financial Advisor in Advance of the Rights Offering Expiration on January 10, 2025 
From CytoSorbents
Via GlobeNewswire
News headline image
CytoSorbents to Host Investor Meetings in San Francisco During J.P. Morgan Healthcare Conference Week
From CytoSorbents
Via GlobeNewswire
News headline image
CytoSorbents Announces Rights Offering
Investors Must Hold or Buy CTSO Common Stock by Close of Nasdaq Trading on Friday, December 13, 2024 to Participate 
From CytoSorbents
Via GlobeNewswire
News headline image
CytoSorbents to Participate at the Piper Sandler 36th Annual Healthcare Conference
From CytoSorbents
Via GlobeNewswire
News headline image
CytoSorbents And Converge Biotech Announce Strategic Partnership to Expand Sepsis and Critical Care Treatment with CytoSorb in India
From CytoSorbents; Converge Biotech
Via GlobeNewswire
News headline image
CytoSorbents Reports Third Quarter 2024 Financial and Operational Results
From CytoSorbents
Via GlobeNewswire
News headline image
CytoSorbents Submits Health Canada Medical Device License Application for DrugSorb-ATR Following MDSAP Certification
From CytoSorbents
Via GlobeNewswire
News headline image
FDA Accepts DrugSorb-ATR De Novo Application To Reduce the Severity of CABG-Related Bleeding Due to Ticagrelor and Initiates Substantive Review
DrugSorb™-ATR is an FDA Breakthrough Device eligible for priority review with an FDA decision anticipated in 2025 
From CytoSorbents
Via GlobeNewswire
News headline image
CytoSorbents to Report Third Quarter 2024 Operating and Financial Results
From CytoSorbents
Via GlobeNewswire
News headline image
CytoSorbents Submits DrugSorb-ATR Marketing Application to U.S. FDA to Reduce the Severity of Bleeding in Heart Bypass Surgery Patients on the Blood Thinner Ticagrelor and Provides Business Update
From CytoSorbents
Via GlobeNewswire
News headline image
CytoSorbents to Present at the H.C. Wainwright 26ᵗʰ Annual Global Investment Conference
From CytoSorbents
Via GlobeNewswire
News headline image
CytoSorbents Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From CytoSorbents
Via GlobeNewswire
News headline image
CTSO Stock Earnings: CytoSorbents Beats EPS, Beats Revenue for Q2 2024 ↗
CTSO stock results show that CytoSorbents beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
News headline image
CytoSorbents Reports Second Quarter 2024 Financial and Operational Results
From CytoSorbents
Via GlobeNewswire
News headline image
CytoSorbents Appoints Peter J. Mariani Chief Financial Officer
CytoSorbents CFO Kathleen P. Bloch Retires 
From CytoSorbents
Via GlobeNewswire
News headline image
CytoSorbents to Report Second Quarter 2024 Operating and Financial Results
From CytoSorbents
Via GlobeNewswire
News headline image
CytoSorbents Announces Compliance with Nasdaq Minimum Bid Price Requirement
From CytoSorbents
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.